Three experts discuss the impact of digital therapeutics (DTx) and prescription digital therapeutics (PDTs) as behavioral health therapy, from benefits to the treatment space to potential improvements and unmet needs.
EP. 1: Understanding DTx and PDTs
A distinguished panel provides an overview of what digital therapeutics (DTx) and prescription digital therapeutics (PDTs) are and how they’re used in behavioral health treatment.
EP. 2: Considering DTx and PDTs as Part of Treatment
Arwen Podesta, MD; Timothy Aungst, PharmD; and Scottle Whittle, MD, explain the considerations they think about before using or prescribing DTx and PDTs.
EP. 3: Monitoring Patients Through DTx and PDTs
Clinicians, pharmacists, and payers discuss how DTx and PDTs are monitored—for access, efficacy, adherence, and more.
EP. 4: Using PDTs Evidence to Explain the FDA Approval Process
Scott Whittle, MD, uses his knowledge and experiences as a payer—with the help of the other panelists—to explain how the FDA uses gathered evidence to make decisions on approvals for PDTs.
EP. 5: Comparing PDTs With More Conventional Therapies
Medical authorities detail how PDTs are compared with other, more conventional treatment modalities in behavioral health.
EP. 6: Durability of DTx and PDTs
Drs Whittle and Podesta discuss the durability and stability of DTx and PDT treatment.
EP. 7: DTx, PDTs, and Cost Savings for Payers
Scott Whittle, MD, and Arwen Podesta, MD, confer about cost savings from digital therapeutics and prescription digital therapeutics from payer and provider perspectives.
EP. 8: Using Real-World Evidence to Advocate for DTx and PDTs
A panel of specialists focus on how real-world evidence affects the use and acceptance of digital therapeutics and prescription digital therapeutics, as well as FDA approvals.
EP. 9: DTx and PDT Access
Drs Podesta and Aungst elaborate on DTx and PDT access and the impact these therapeutics can have in the behavioral health treatment landscape.
EP. 10: PDT Coverage: Pharmacy or Medical Benefit?
Three doctors discuss whether PDTs should be covered as a pharmacy benefit or medical benefit.
EP. 11: Closing Thoughts on DTx and PDTs
Our panel concludes with their final thoughts on using DTx and PDT management.
2 Clarke Drive Cranbury, NJ 08512